Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.

Cybulski C, Wokołorczyk D, Kluźniak W, Kashyap A, Gołąb A, Słojewski M, Sikorski A, Puszyński M, Soczawa M, Borkowski T, Borkowski A, Antczak A, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Domagała P, Piotrowski K, Menkiszak J, Krzystolik K, Gronwald J, Jakubowska A, Górski B, Dębniak T, Masojć B, Huzarski T, Muir KR, Lophatananon A, Lubiński J, Narod SA; Polish Hereditary Prostate Cancer Consortium.

Br J Cancer. 2013 Jun 25;108(12):2601-9. doi: 10.1038/bjc.2013.261. Epub 2013 May 30.

2.

An inherited NBN mutation is associated with poor prognosis prostate cancer.

Cybulski C, Wokołorczyk D, Kluźniak W, Jakubowska A, Górski B, Gronwald J, Huzarski T, Kashyap A, Byrski T, Dębniak T, Gołąb A, Gliniewicz B, Sikorski A, Switała J, Borkowski T, Borkowski A, Antczak A, Wojnar L, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Sikorska-Radek P, Matych J, Wilkosz J, Różański W, Kiś J, Bar K, Bryniarski P, Paradysz A, Jersak K, Niemirowicz J, Słupski P, Jarzemski P, Skrzypczyk M, Dobruch J, Domagała P, Narod SA, Lubiński J; Polish Hereditary Prostate Cancer Consortium.

Br J Cancer. 2013 Feb 5;108(2):461-8. doi: 10.1038/bjc.2012.486. Epub 2012 Nov 13.

3.

A novel founder CHEK2 mutation is associated with increased prostate cancer risk.

Cybulski C, Huzarski T, Górski B, Masojć B, Mierzejewski M, Debniak T, Gliniewicz B, Matyjasik J, Złowocka E, Kurzawski G, Sikorski A, Posmyk M, Szwiec M, Czajka R, Narod SA, Lubiński J.

Cancer Res. 2004 Apr 15;64(8):2677-9.

4.

The presence of prostate cancer at biopsy is predicted by a number of genetic variants.

Kashyap A, Kluźniak W, Wokołorczyk D, Gołąb A, Sikorski A, Słojewski M, Gliniewicz B, Świtała J, Borkowski T, Borkowski A, Antczak A, Wojnar Ł, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Sikorska-Radek P, Matych J, Wilkosz J, Różański W, Kiś J, Bar K, Bryniarski P, Paradysz A, Jersak K, Niemirowicz J, Słupski P, Jarzemski P, Skrzypczyk M, Dobruch J, Domagała P, Piotrowski K, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Dębniak T, Górski B, Masojć B, van de Wetering T, Menkiszak J, Akbari MR, Lubiński J, Narod SA, Cybulski C; Polish Hereditary Prostate Cancer Consortium.

Int J Cancer. 2014 Mar 1;134(5):1139-46. doi: 10.1002/ijc.28447. Epub 2013 Sep 16.

5.

Utility of incorporating genetic variants for the early detection of prostate cancer.

Nam RK, Zhang WW, Trachtenberg J, Seth A, Klotz LH, Stanimirovic A, Punnen S, Venkateswaran V, Toi A, Loblaw DA, Sugar L, Siminovitch KA, Narod SA.

Clin Cancer Res. 2009 Mar 1;15(5):1787-93. doi: 10.1158/1078-0432.CCR-08-1593. Epub 2009 Feb 17.

6.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

7.

A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.

Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, Masojć B, Jakubowska A, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Zdrojowy R, Małkiewicz B, Borkowski A, Borkowski T, Szwiec M, Narod SA, Lubiński J.

J Med Genet. 2006 Nov;43(11):863-6.

8.

CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.

Bayram S, Topaktaş M, Akkız H, Bekar A, Akgöllü E.

Cancer Epidemiol. 2012 Oct;36(5):453-7. doi: 10.1016/j.canep.2012.03.008. Epub 2012 Apr 20.

PMID:
22521562
9.

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.

10.

The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.

Palmerola R, Smith P, Elliot V, Reese CT, Mahon FB, Harpster LE, Icitovic N, Raman JD.

Can J Urol. 2012 Dec;19(6):6542-7.

PMID:
23228289
11.

The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome.

Lener MR, Kashyap A, Kluźniak W, Cybulski C, Soluch A, Pietrzak S, Huzarski T, Gronwald J, Lubiński J.

Cancer Res Treat. 2017 Apr;49(2):430-436. doi: 10.4143/crt.2016.217. Epub 2016 Jul 28.

12.

Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?

Lener MR, Scott RJ, Kluźniak W, Baszuk P, Cybulski C, Wiechowska-Kozłowska A, Huzarski T, Byrski T, Kładny J, Pietrzak S, Soluch A, Jakubowska A, Lubiński J.

Int J Cancer. 2016 Aug 1;139(3):601-6. doi: 10.1002/ijc.30116. Epub 2016 Apr 18.

13.
14.

Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.

Törnblom M, Norming U, Adolfsson J, Becker C, Abrahamsson PA, Lilja H, Gustafsson O.

Urology. 1999 May;53(5):945-50.

PMID:
10223488
15.

Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.

Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, Lévesque J, Brousseau G, Bélanger A, Labrie F.

Prostate. 2000 Sep 15;45(1):19-35.

PMID:
10960839
16.

Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.

Novak DJ, Chen LQ, Ghadirian P, Hamel N, Zhang P, Rossiny V, Cardinal G, Robidoux A, Tonin PN, Rousseau F, Narod SA, Foulkes WD.

BMC Cancer. 2008 Aug 15;8:239. doi: 10.1186/1471-2407-8-239.

17.
18.

Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML.

Int J Cancer. 2007 Dec 15;121(12):2661-7.

19.

Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.

20.

Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.

Liss MA, Xu J, Chen H, Kader AK.

Prostate. 2015 Sep;75(12):1322-8. doi: 10.1002/pros.23012. Epub 2015 May 15.

PMID:
25982801

Supplemental Content

Support Center